Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
clostridium butyricum + lactobacillus
- Development stage
- Unknown
- Lead developer
- Miyarisan Pharmaceutical
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This combination probiotic therapy consists of Clostridium butyricum and Lactobacillus species (most commonly Lactobacillus acidophilus). Clostridium butyricum is a gram-positive, anaerobic, spore-forming bacterium that produces butyric acid, a short-chain fatty acid (SCFA) essential for the health of colonocytes and the maintenance of the intestinal epithelial barrier. Lactobacillus species are lactic acid-producing bacteria that lower intestinal pH, thereby inhibiting the growth of pathogenic bacteria and stimulating local mucosal immunity. Together, these organisms work synergistically to restore gut microbiota balance, enhance the intestinal barrier, and prevent the translocation of bacteria into the bloodstream. This is particularly relevant for immunocompromised patients, such as those undergoing chemotherapy for head and neck cancers, where intestinal damage can lead to repeated sepsis.
- Brand names
- Bio-ThreeLacbonMiyarisan
- Other names
- Clostridium butyricum and Lactobacillus acidophilus combined capsulesClostridium butyricum and Lactobacillus acidophilusC. butyricum + Lactobacillus
Beyond the preview
Go deeper on clostridium butyricum + lactobacillus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on clostridium butyricum + lactobacillus.